Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma

Chest

Volumn 115, Issue 2, 1999, Pages 343-351

  Gross, Gary ^a   Thompson, Philip J ^b   Chervinsky, Paul ^c   Vanden Burgt, Jennifer ^d   Bleecker, Eugene ^e   Briggs, Dick ^e   Bronsky, Edwin ^e   Brooks, Stuart ^e   Sonia Buist, A ^e   Diamond, Edward ^e   Dockhorn, Robert ^e   Edwards, Thomas ^e   Galant, Stanley ^e   Grossman, Jay ^e   Charles Hiller, F ^e   Kaiser, Harold ^e   Kaye, Mitchell ^e   Lawrence, Michael ^e   Montanero, Anthony ^e   Morris, Richard ^e   Nathan, Robert ^e   Ostrom, Nancy ^e   Pearlman, David ^e   Prenner, Bruce ^e   Ramsdell, Joe ^e   Southern, Loren ^e   Tinkelman, David ^e   Virant, Frank ^e   Wanderer, Alan ^e   more..

^a Dallas Allergy & Asthma Center   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c New England Clinical Studies   (United States)

^d 3M COMPANY   (United States)

^e Building 270 3A 01 ^*

Author keywords

Chlorofluorocarbon beclomethasone dipropionate; Hydrofluoroalkane 134a beclomethasone dipropionate; Moderate asthma

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; FLUORINATED HYDROCARBON; PREDNISOLONE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032962435     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.2.343     Document Type: Article

References (36)

1. Global initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health NHLBI/WHO workshop report; 1995; National Institutes of Health publication 95-3659
2. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. NIH publication No. 97-4051. Bethesda, MD: National Institutes of Health, 1997
3. Jackson C, Lipworth B. Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract 1995; 45:683-687
4. Newman SP, Pavia D, Clarke SW. Improving the bronchial deposition of pressurized aerosols. Chest 1981; 80:909-914
5. Thompson P. Drug delivery to the small airways. Am J Respir Crit Care Med 1998; 157(suppl):S199-S202
6. Woolcock A. Effects of drugs on small airways. Am J Respir Crit Care Med 1998; 157(suppl):S203-S207
7. Laube BL. In vivo measurements of aerosol dose and distribution: clinical relevance. J Aerosol Med 1996; 9(suppl 1):S77-S92
8. Leach CL. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol 1995; 22:328-334
9. Leach CL, Davidson P, Heilman J, et al. Improved lung deposition and decreased oropharyngeal deposition with a new CFC-free beclomethasone metered dose inhaler. Am J Respir Crit Care Med 1997; 155:A667
10. June DS, Schultz RK, Miller NC. A conceptual model for the delivery of pressurized metered-dose hydrofluoroalkane-based inhalation aerosols. Pharm Technol 1994; 18:40-52
11. June DS, Schultz DW. Improved performance characteristics of CFC-free aerosol MDIs. J Aerosol Med 1995; 8:91
12. Leach CL. Enhanced drug delivery through reformulating MDIs with HFA propellants - drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Bryon PR, Farr SJ, eds. Respiratory drug delivery V proceedings. Buffalo Grove, IL: Interpharm Press, 1996; 133-144
13. Warren SJ, Rowe AM, Taylor G. Efficient lung deposition of beclomethasone dipropionate via a novel multidose dry powder inhaler compared to a conventional pressurized metered dose inhaler. Pharm Res 1997; 14(suppl):S131-S132
14. Standardization of spirometry - 1987 update: statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136:1285-1298
15. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680
16. Schuirmann DJ. Design of bioavailability/bioequivalence studies. Drug Inf J 1990; 24:315-333
17. Alexander DJ. Safety of propellants. J Aerosol Med 1995; 8(suppl 1):S42-S47
18. Dockhorn R, Vanden Burgt JA, Ekholm BP, et al. Clinical equivalence of a novel nonchlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995; 96:50-56
19. Jenkins M. Clinical evaluation of CFC-free metered dose inhalers. J Aerosol Med 1995; 8(suppl 1):S41-S47
20. Davie RJ, Stampone P, O'Connor BJ. HFA-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to CFC beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92(suppl A): 23-31
21. Wong BJO, Hargreave FE. Bioequivalence of metered-dose inhaled medications. J Allergy Clin Immunol 1993; 92:373-379
22. Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet 1994; 26:1-6
23. Derom E, Pauwels R. Bioequivalence of inhaled drugs. Eur Respir J 1995; 8:1634-1636
24. Fuller RW, Hallett C, Dahl R. Assessing equivalence of inhaled drugs. Respir Med 1995; 89:525-527
25. Rogers DF, Ganderton D. Determining equivalence of inhaled medications. Respir Med 1995; 89:253-261
26. Zanen P, Lammers J-WJ. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995; 48:179-184
27. Jones B, Jarvis P, Lewis JA, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313:36-39
28. Snell NJC. Assessing equivalence of inhaled products. J Pharm Pharmacol 1997; 49(suppl 3):55-60
29. Toogood JH, Baskerville J, Jennings B, et al. Personal observations on the use of inhaled corticosteroid drugs for chronic asthma. Eur J Respir Dis 1984; 65:321-328
30. Szefler SJ, Leung DYM. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 1997; 10:1640-1647
31. Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993; 58:173-209
32. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868-875
33. Adcock IM. Steroid resistance in asthma: molecular mechanisms. Am J Respir Crit Care Med 1996; 154(suppl 2):S58-S61
34. Barnes PJ, Adcock IM. Steroid resistance in asthma. Q J Med 1995; 88:455-468
35. Barnes PJ, Pederson S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157:S1-S53
36. 1 as HFA-BDP. Chicago, IL: American Thoracic Society International Conference, 1998